OTCMKTS:QBIO - Q BioMed Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.60
▼ -0.0427 (-6.65%)

This chart shows the closing price for QBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Q BioMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QBIO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Q BioMed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.60.

This chart shows the closing price for QBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Q BioMed. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/10/2019Brookline Capital ManagementReiterated RatingBuy
11/29/2018Roth CapitalDowngradeBuy ➝ Neutral$6.75 ➝ $1.85
6/28/2018Roth CapitalInitiated CoverageBuy$6.75
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/18/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/18/2021

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Q BioMed logo
Q BioMed, Inc. operates as a biomedical acceleration and development company. It focuses on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Its products include Strontium-89, MetastronTM, QBM-001, Uttroside-B, and MAN 01. The company was founded by Enrique Navas on November 22, 2013 and is headquartered in New York, NY.
Read More

Today's Range

Now: $0.60
Low: $0.58
High: $0.65

50 Day Range

MA: $0.72
Low: $0.60
High: $0.86

52 Week Range

Now: $0.60
Low: $0.58
High: $1.59

Volume

145,700 shs

Average Volume

77,995 shs

Market Capitalization

$17.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Q BioMed?

The following sell-side analysts have issued stock ratings on Q BioMed in the last twelve months:
View the latest analyst ratings for QBIO.

What is the current price target for Q BioMed?

0 Wall Street analysts have set twelve-month price targets for Q BioMed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Q BioMed in the next year.
View the latest price targets for QBIO.

What is the current consensus analyst rating for Q BioMed?

Q BioMed currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for QBIO.

How do I contact Q BioMed's investor relations team?

Q BioMed's physical mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The company's listed phone number is (646) 889-2226. The official website for Q BioMed is www.qbiomed.com.